Evidence map›Paper›PMID 33646527›Full record

Trial reportInternational journal of hematology2021

Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment.

Yumei Liu, Chen Yang, Hua Xue, Fang Ye, Wanling Sun, Jingbo Wang, Weiwei Qi, Haiyue Niu, Luoming Hua, Huaquan Wang and 2 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Yumei Liu *Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China.
Chen Yang *Department of Hematology, Peking Union Medical Colleague Hospital, Chinese Academe of Medical Science, Beijing, China.
Hua Xue *Department of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China.
Fang YeDepartment of Hematology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, 100022, China.
Wanling SunDepartment of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Jingbo WangDepartment of Hematology, Aerospace Center Hospital, Aerospace School of Clinical Medicine, Peking University, Beijing, China.
Weiwei QiDepartment of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China.
Haiyue NiuDepartment of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China.
Luoming HuaDepartment of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China.
Huaquan WangDepartment of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China. wanghuaquan@tmu.edu.cn.
Bing HanDepartment of Hematology, Peking Union Medical Colleague Hospital, Chinese Academe of Medical Science, Beijing, China. hanbing_li@sina.com.cn.
Zonghong ShaoDepartment of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China. shaozonghong@tmu.edu.cn.ORCID http://orcid.org/0000-0003-4966-2956
Tianjin Medical University General Hospital · CNAffiliated Hospital of Hebei University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Chuiyangliu Hospital · CNCapital Medical University · CNPeking University · CN

Funding

Beijing Natural Science Foundation 7192168Key Technology Research and Development Program of Tianjin China 18ZXDBSY00140National Natural Science Foundation 81170472National Natural Science Foundation of China 81970116National Natural Science Foundation of China (CN) 81770118Natural Science Foundation of Tianjin China 16JCZDJC35300the Chinese Academy of Medical Sciences (CAMS) innovation for medical sciences 2016-I2M-3-004
6 · The paper itself

Abstract

It is unknown whether adding stanozolol to decitabine for maintenance can further improve progression-free survival (PFS) and overall survival (OS) after effective decitabine treatment in patients with high-risk myelodysplastic syndrome (MDS). Patients newly diagnosed with high-risk MDS who achieved at least partial remission after 4 cycles of decitabine (20 mg/m

Indexed as

AdultAgedDecitabineDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedMyelodysplastic SyndromesStanozololSurvival RateDecitabineStanozololDecitabineMaintenance treatmentMyelodysplastic syndromeStanozolol

Identifiers

PMID33646527
OpenAlexW3135599719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.